



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on July 13, 2005

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1632
Patent Application
Docket No. USF-182XC1
Serial No. 10/655,873

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1632
Applicants : Shyam S. Mohapatra, Mukesh Kumar
Serial No. : 10/655,873
Filed : September 5, 2003
Conf. No. : 6872
For : Genetic Adjuvants for Immunotherapy

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/655,873
Filing Date	September 5, 2003
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1632
Examiner Name	Louis D. Lieto
Attorney Docket Number	USF-182XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	KUMAR, M. <i>et al.</i> "IFN- γ and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy" <i>J. Allergy Clin Immunol.</i> , September 2001, 108:402-408.	
	R2	NONAKA, M. <i>et al.</i> "Induction of eotaxin production by interleukin-4, interleukin-13 and lipopolysaccharide by nasal fibroblasts" <i>Clin. Exp. Allergy</i> , 2004, 34:804-811.	
	R3	UPTON, C. <i>et al.</i> "Encoding of a homolog of the IFN- γ receptor by myxoma virus" <i>Science</i> , 1992, 258:1369-1372.	
	R4	VANDENBROECK, K. <i>et al.</i> "The conserved helix C region in the superfamily of interferon- γ /interleukin-10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK" <i>J. Biol. Chem.</i> , 2002, 277:25668-25676.	
	R5	ZHU, Z. <i>et al.</i> "Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation" <i>Science</i> , 2004, 304:1678-1682.	
	R6	"Immunocytokines - Local Stimulation of the Immune System", 2002, www.merck.at/produkte/immunozytokine.pdf .	
	R7	STALLMACH, A. <i>et al.</i> "An Interleukin 12 p40-IgG2b Fusion Protein Abrogates T Cell Mediated Inflammation: Anti-Inflammatory Activity in Crohn's Disease and Experimental Colitis <i>In Vivo</i> ", <i>Gut</i> , 2004, pp. 339-345, Vol. 53.	
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.